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ABSTRACT
INTRODUCTION: The Auckland chlamydia pilot project was one of three funded by the Ministry of 
Health to trial implementation of the 2008 Chlamydia Management Guidelines. Chlamydia is the most 
commonly notified sexually transmitted infection in New Zealand.
AIM: To increase opportunistic testing in under-25-year-olds and to improve documentation of partner 
notification in primary care.
METHODS: A four-month pilot was initiated in Total Healthcare Otara using a nurse-led approach. Labo-
ratory testing data was analysed to assess whether the pilot had any impact on chlamydia testing volumes 
in the target age-group. Data entered in the practice management system was used to assess follow-up 
and management of chlamydia cases.
RESULTS: During the pilot there was a 300% increase in the number of chlamydia tests in the target age-
group from 812 to 2410 and the number of male tests increased by nearly 500%. Twenty-four percent of 
people tested were positive for chlamydia, with no significant difference in prevalence by ethnicity. The 
pilot resulted in better documentation of patient follow-up in the patient management system.
DISCUSSION: There was a large increase in chlamydia testing during the pilot with a high prevalence 
found in the population tested. Chlamydia remains an important health problem in New Zealand. The 
cost benefit of increased chlamydia screening at a population level has yet to be established.
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Introduction
The Auckland chlamydia pilot was one of three 
pilots funded by the Ministry of Health to trial 
implementation of the 2008 Chlamydia Manage-
ment Guidelines.1 Chlamydia is the most com-
monly notified sexually transmitted infection 
(STI) in New Zealand2 and can result in signifi-
cant adverse sequelae including peri-hepatitis and 
pelvic inflammatory disease (PID).3–5 Environ-
mental Science and Research services (ESR) labo-
ratory surveillance data indicate that over 70% 
of chlamydia cases are diagnosed in those aged 
under 25 years and rates of diagnosis are higher 
in those of Maori and Pacific ethnicity.2 The 
ESR data also indicate disproportionate numbers 
of chlamydia cases are diagnosed in females. Data 
from the Waikato pilot confirmed a lower test 
uptake in males.6
The Auckland pilot had multiple aims and objec-
tives. This paper describes outcomes of two aims: 
firstly, to increase opportunistic testing for chla-
mydia in those aged under 25 years (particularly 
males) and, secondly, to improve documentation 
of follow-up and partner notification of diag-
nosed cases. As previous research has indicated 
that nurse-led opportunistic testing is very suc-
cessful at increasing chlamydia testing rates,7 we 
opted to utilise this approach. 
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Methods
A South Auckland primary care setting was chosen 
for the pilot because of the youthful population 
demographics and the relatively high proportion of 
young Maori and Pacific people in the region. To-
tal Healthcare Otara (THO) agreed to implement 
a four-month pilot project in their 10 primary care 
practices. The limited time period was imposed 
due to Ministry of Health time constraints. 
whether there had been any risk of re-infection, 
to check whether sexual contacts had been noti-
fied and to offer a repeat chlamydia test in three 
months’ time. 
Laboratory testing data was obtained from the 
community laboratory. A reference sample of data 
from a four-month period 12 months prior to the 
introduction of the pilot (pre-pilot period) and a 
second set of chlamydia testing data during the 
pilot implementation period (pilot period) was 
requested for all tests processed in the target age 
group. The laboratory data included age and gen-
der, but not ethnicity. During the pilot period, 
ethnicity data was extracted from the practice 
management system (PMS); THO had introduced 
a new MedTech32 template to the PMS specifi-
cally for the pilot. 
A positive chlamydia test was only counted once 
if there was more than one positive test for an in-
dividual within a one-month period (as PCR tests 
can remain positive for several weeks after treat-
ment) and individuals were counted only once if 
they were re-tested within a one-month period. 
There was some contamination of the laboratory 
data, as the reports also contained data from three 
practices in the same region not included in the 
pilot because they used the same laboratory refer-
ence code. 
Statistical analysis
The two-proportion z-score test was used to 
determine whether observed differences between 
Table 1. Chlamydia testing: laboratory data
Pre-pilot Pilot
All
N (%)
Male
n (%)
Female
n (%)
Age
14–19
n (%)
Age
20–24
n (%)
All
N (%)
Male
n (%)
Female
n (%)
Age
14–19
n (%)
Age
20–24
n (%)
Total no. tests 812 (100) 144 (17.7) 668 (82.3) 281 (34.6) 509 (62.7) 2410 (100) 695 (28.8) 1715 (71.2) 916 (38.0) 1466 (60.8)
No. individuals 
tested 760 (93.6) 130 (90.3) 630 (94.3) 254 (90.4) 484 (95.1) 2157 (89.5) 658 (94.7) 1499 (87.4) 815 (89.0) 1315 (89.7)
No. positive 
tests 194 (23.9) 59 (41.0) 135 (20.2) 83 (32.7) 109 (22.5) 618 (76.1) 155 (21.3) 370 (22.0) 251 (30.8) 262 (19.9)
% individuals 
positive* 25.5 45.4 21.4 32.7 22.5 24.3 23.6 24.7 30.8 19.9
*  After exclusion of duplicates.
Chlamydia testing in primary care is already 
known to be acceptable and to be regarded 
positively by young people if given in the 
right environment.
THO operates by a nurse-triage process and during 
the pilot period a chlamydia test was to be offered 
by the nurses to all sexually active under-25-year-
olds, using criteria recommended in the chlamydia 
management guidelines. If consent was given, 
males provided a first-pass urine specimen and 
females obtained a self-collected vaginal swab for 
testing. Laminated instruction cards were provided 
to explain how to collect their vaginal sample. 
All patients testing positive for chlamydia were 
to be recalled by a registered nurse for treatment 
and to discuss partner notification. It was recom-
mended that all cases should receive a follow-up 
telephone call one week after treatment to check 
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WHAT GAP THIS FILLS
What we already know: Chlamydia is the commonest sexually transmit-
ted infection notified in New Zealand. Opportunistic testing is recommended 
in the under-25-year-old age group. However, test uptake in males is much 
lower than females in primary health care settings.
What this study adds: Nurse-led opportunistic testing for chlamydia 
in primary health care is successful at increasing testing in both males and 
females. It is possible to improve documentation of partner notification in 
primary health care, but further research is needed in this area.
the pre-pilot and pilot data were significant. Prob-
ability values were calculated from the z-scores 
using a normal distribution calculator and a 
significance level of 0.05 was used.
Ethical approval was obtained for the project 
from the Northern Regional Ethics Committee 
(Ref. NTX/10/EXP/169). The pilot project im-
plementation commenced 6 December 2010 and 
finished 31 March 2011.
Results
During the pre-pilot period, THO provided con-
sultations to 2746 patients in the target age group 
and 812 chlamydia tests were processed by the 
laboratory, which corresponded to 760 individu-
als after exclusion of duplicates. Table 1 shows 
the laboratory testing data. As noted in the 
methods section, some of these individuals would 
have been tested outside of the pilot setting. The 
majority of chlamydia tests were requested in 
females (82%) and, overall, 26% of individuals 
tested were positive. The percentage of positive 
tests in males was nearly double that of females. 
Males and females in the 14- to 19-year age group 
tested positive more frequently than those in the 
20- to 24-year age group, but this difference was 
only significant for females (p=0.006).
During the pilot period, data from the PMS in-
dicated that 3687 patients in the target age group 
were triaged by THO and 1715 of these patients 
(46%) were tested for chlamydia. The numbers 
of chlamydia tests processed by the laboratory 
increased dramatically from 812 tests to 2410 
(just over 300%) and the number of male tests 
increased by nearly 500%, from 144 to 695 tests. 
The proportion of male tests increased from 18% 
to 29% of total tests. The PMS data revealed that 
a similar proportion of males (47%) and females 
(45%) presenting to THO during the pilot period 
were tested for chlamydia. Overall, 24% of people 
tested were positive which was similar to the 
pre-pilot period. The test positivity rate in males, 
however, declined considerably from pre-pilot 
levels (p<0.001). 
The ethnic distribution of registered THO 
patients in the target age group during the pilot 
was predominantly Pacific (57%), followed by NZ 
Maori (18%), European (includes NZ and other 
European; 7%), Asian (6%), and Others (4%), with 
ethnicity data missing for 8%. Ethnicity data 
is shown in Table 2. Chlamydia test positivity 
was highest in those of Pacific ethnicity (19%), 
but this was not significantly higher than for 
NZ Maori (p=0.35), European (p=0.28), or those 
of Other ethnicity (p=0.89). Test positivity in 
Asians, however, was significantly lower than all 
other ethnicities (p=0.01). 
Laboratory specimen data is shown in Table 3.
There was a shift in practice during the pilot 
period to the offering of self-collected vaginal 
swabs to females for opportunistic testing rather 
Table 2. Chlamydia testing: ethnicity data 
Pacific
n (%)
NZ Maori 
n (%)
Asian 
n (%)
European 
n (%)
Other 
n (%)
Missing 
n (%)
Total 
N (%)
Assessments 2117 (57) 649  (18) 212 (6) 274 (7) 150  (4) 285 (8) 3687 (100)
Total tests 1062 (62) 396 (23) 45 (3) 114 (7) 35 (2) 63 (3) 1715 (100)
Female tests 669 (60) 283 (25) 28 (2) 92 (8) 22 (2) 30 (3) 1124 (66)
Male tests 393 (66) 113  (19) 17 (3) 22 (4) 13 (2) 33 (6) 591 (34)
Positive tests 202 (19) 68 (17) 2 (5) 18 (16) 3 (2) 7 (2) 300 (17)
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than urine specimens; prior to the pilot, many 
THO clinical staff had thought this approach to 
testing would not be acceptable to young women. 
The numbers of male urine specimens increased 
from 12% to 27% of total specimens (p<0.001). 
The pilot also resulted in recording of more 
information in the PMS regarding follow-up and 
outcomes of partner notification. Prior to the 
pilot, no documentation was kept on follow-up 
of partner notification activities. Data from the 
PMS indicated that 25% (n=75) of treated cases 
had had unprotected sex in the week after treat-
ment; 64% of cases reported they had notified 
sexual contacts.
Discussion
The Auckland pilot had a dramatic effect on 
increasing the volume of chlamydia testing in 
under-25-year-olds, particularly in males. Chla-
mydia testing in primary care is already known 
to be acceptable and to be regarded positively by 
young people if given in the right environment.8 
Previous New Zealand research has found that 
self-testing is a preferred option for many women 
and vaginal swabs have good acceptability.9 
Unfortunately, we cannot comment on test up-
take in our study as no documentation was kept 
regarding how many people were offered testing 
or how many declined testing. The other main 
weakness of this study was the contamination 
of the laboratory data with non-pilot partici-
pants. However, the increase in test volumes 
was of such a magnitude that it is probably safe 
to assume the pilot was largely responsible for 
the increase. 
There are a number of factors that probably 
enhanced the effects of this pilot project. Firstly, 
the visits were free. Previous research in New 
Zealand has shown that free sexual health 
consultations in primary care markedly increases 
chlamydia test coverage and case detection rates, 
and that, therefore, efforts should be made to re-
duce cost barriers for young people seeking care 
for sexual health needs.10 Secondly, the use of 
trained practice nurses probably enhanced uptake 
of testing as was found in a previous pilot study 
in Wellington, where nurse-led testing achieved 
the greatest test coverage.7 Thirdly, normalis-
ing chlamydia testing by making it standard 
practice to offer it to all sexually active young 
people reduced stigma and probably made it more 
acceptable.8 
The increase in testing in the Wellington pilot 
was not as dramatic as in the Auckland pilot. 
That pilot project differed in some respects—in-
centives were used and it did not report specifi-
cally on gender breakdown of the increased test 
coverage. The effect on increased testing did not 
persist after the Wellington pilot finished. 
There was a disturbingly high prevalence of 
chlamydia in this South Auckland population, 
particularly in young women aged 14 to 19 years. 
Table 3. Chlamydia testing: laboratory specimen type data
Specimen type
Pre-pilot
n (%)
Pilot 
n (%)
p-value
Male urine 94 (11.6) 654 (27.2) <0.0001
Female urine 89 (11.0) 252 (10.5) 0.68629
Vulval/vaginal swab 22 (2.7) 156 (6.5) <0.00005
Vulval/vaginal self-collected swab 0 (0) 302 (12.5) <0.0001
Cervical swab 523 (64.4) 968 (40.2) <0.0001
Urethral/urogenital swab  58 (7.1) 36 (1.5) <0.0001
Unspecified 3 (0.4) 18 (0.7) 0.24771
Missing 23 (2.8) 24 (0.8) <0.0001
TOTAL 812 2410
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Whilst the major shift from diagnostic to op-
portunistic testing during the pilot project was 
associated with a decreased prevalence of positive 
tests, particularly in males, overall in the under-
25-year age group, the positive test rate was more 
than twofold higher than the 9% reported in the 
2011 ESR laboratory surveillance data.2 Females 
accounted for the majority of chlamydia tests in 
the pilot and this was a similar finding to testing 
patterns in other primary care settings. Data 
from the much bigger Waikato pilot found there 
was much lower chlamydia test uptake in males 
than in females.6 In contrast to the Waikato pilot 
and other data,2 we did not find the prevalence 
of chlamydia to be higher in those of Maori and 
Pacific ethnicity compared with Europeans. 
There was better documentation of partner noti-
fication and follow-up during the pilot and this 
was encouraging. This is an area of case manage-
ment of STIs that urgently needs addressing.11 
It should not be too difficult to improve with 
appropriate training and systems, as it has been 
shown that trained practice nurses can achieve as 
good outcomes for partner notification for chla-
mydia as specialist sexual health clinic advisors.12 
Good follow-up of cases is important, as there is 
a high rate of re-infection.13
In conclusion, there was a large increase in 
chlamydia testing during the pilot project, but it 
is doubtful that this is sustainable and the cost 
benefit of the testing has yet to be established.14 
However, the very high prevalence of chlamydia 
and recent evidence of much higher rates of 
hospital admissions for chlamydia-related PID in 
New Zealand compared with other countries,15 
indicates chlamydia continues to be a very signif-
icant health problem for young people presenting 
to primary care. 
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